A couple weeks ago I saw that there were two cups but no saucer. So one of the gurus cited Investors Bus Daily that this baby was gonna pop.
After following this stock for more than six years when it was at 80 cents and knowing that major pharmceuticals were sharking around it seemed this stock might one day really pop. I talked to the CFO back then for what good that did.
So after all these years I finally made a move on the stock. With Pfizer in the wings, they could pounce at any time. This diabetes thing sounds pretty good and Pfizer needs new products. No telling how long it will take for FDA approval.
In the meantime, I liked their attitude toward research as not much viable research is going on in the Pharmaceutical Industry and that has been the case for many years. Wyeth outsourced their research to contractors to come up with some new stuff in the last ten years and look what happened to them. I know they brought these contractors in house to develop new products. I know/knew one of their contractors who was there ten years or more and believe Pfizer kept him on in the same capacity but maybe hired him as a Pfizer employee. The contractor approach turned their whole R&D around and they started coming up with new products. Funny thing.
PFE just may be poised to jump in when the Nestle deal closes and the last of this years warrants expire in July, this summer. No news on HSS, Neuron Systems, or phase 1- 2 of the Pfizer dose study. I think by fall we'll see some real activity with the outstanding shares in this price range. Not to mention the rev's from ALIM marketing partnership deal which should happen in the fall as well. It's not easy to own this stock with it's high beta characteristics.